ReviewNanomedicine (London, England)2016
Nanotechnology in diagnosis and treatment of coronary artery disease.
Review in Nanomedicine (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- A systematic review of nano formulation of natural products for the treatment of inflammatory bowel disease: drug delivery and pharmacological targets.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2018Pooled it
- Reactive Oxygen Species in Cardiovascular and Hematological Diseases: Mechanisms and Therapeutic Strategies.Cureus · 2026Review
- Platelet-derived biomimetic nanoplatforms: a promising drug delivery strategy for cardiovascular disease.Journal of nanobiotechnology · 2025Review
- Potential functional changes in native lysozyme induced by carbon nanotubes studied by molecular dynamics simulations.Scientific reports · 2025Article
- Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis.Molecules (Basel, Switzerland) · 2024Review
- Protective effects of Pt-N-C single-atom nanozymes against myocardial ischemia-reperfusion injury.Nature communications · 2024Article
- Nanotechnology Innovations in Pediatric Cardiology and Cardiovascular Medicine: A Comprehensive Review.Biomedicines · 2024Review
- In Vitro Targeted Delivery of Simvastatin and Niacin to Macrophages Using Mannan-Grafted Magnetite Nanoparticles.ACS omega · 2024Article
- Evolving Diagnostic and Management Advances in Coronary Heart Disease.Life (Basel, Switzerland) · 2023Review
- Hyaluronic Acid-Guided Cerasome Nano-Agents for Simultaneous Imaging and Treatment of Advanced Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Clinical implications of inflammation in atheroma formation and novel therapies in cardiovascular diseases.Frontiers in cell and developmental biology · 2023Review
- Preparation, characterization, and in-vitro cytotoxicity of nanoliposomes loaded with anti-tubercular drugs and TGF-β1 siRNA for improving spinal tuberculosis therapy.BMC infectious diseases · 2022Article
- Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia reperfusion injuries.Bioactive materials · 2022Review
- Designing S100A9-Targeted Plant Virus Nanoparticles to Target Deep Vein Thrombosis.Biomacromolecules · 2021Article
- Carbon Nanotubes: Smart Drug/Gene Delivery Carriers.International journal of nanomedicine · 2021Review
- Light: A Magical Tool for Controlled Drug Delivery.Advanced functional materials · 2020Article
- Combination of the ginsenosides Rb3 and Rb2 exerts protective effects against myocardial ischemia reperfusion injury in rats.International journal of molecular medicine · 2020Article
- Microfluidic Brain-on-a-Chip: Perspectives for Mimicking Neural System Disorders.Molecular neurobiology · 2019Review
- Biological Response to Carbon-Family Nanomaterials: Interactions at the Nano-Bio Interface.Frontiers in bioengineering and biotechnology · 2019Review
- Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.Nanomedicine (London, England) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
Nanotechnology could provide a new complementary approach to treat coronary artery disease (CAD) which is now one of the biggest killers in the Western world. The course of events, which leads to atherosclerosis and CAD, involves many biological factors and cellular disease processes which may be mitigated by therapeutic methods enhanced by nanotechnology. Nanoparticles can provide a variety of delivery systems for cargoes such as drugs and genes that can address many problems within the arteries. In order to improve the performance of current stents, nanotechnology provides different nanomaterial coatings, in addition to controlled-release nanocarriers, to prevent in-stent restenosis. Nanotechnology can increase the efficiency of drugs, improve local and systematic delivery to atherosclerotic plaques and reduce the inflammatory or angiogenic response after intravascular intervention. Nanocarriers have potential for delivery of imaging and diagnostic agents to precisely targeted destinations. This review paper will cover the current applications and future outlook of nanotechnology, as well as the main diagnostic methods, in the treatment of CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.